Document is current
Any future updates will be listed below
-
Authors
Sarkozy, Clémentine
Chartier, Loïc
Ribrag, Vincent
Gressin, Remy https://orcid.org/0000-0002-9188-3501
Geisler, Christian H.
Kluin-Nelemans, Hanneke C.
Thieblemont, Catherine https://orcid.org/0000-0002-9941-2448
Morschhauser, Franck https://orcid.org/0000-0002-3714-9824
Lemonnier, François https://orcid.org/0000-0001-6205-5419
Safar, Violaine
Tessoulin, Benoît https://orcid.org/0000-0001-7600-3329
Oberic, Lucie
Damaj, Ghandi https://orcid.org/0000-0002-4689-3882
Ghesquières, Hervé
Bouabdallah, Krimo
Casasnovas, René Olivier https://orcid.org/0000-0002-1156-8983
Houot, Roch
Klapper, Wolfram https://orcid.org/0000-0001-7208-4117
Burroni, Barbara
Pott, Christiane https://orcid.org/0009-0005-9260-8340
Delfau-Larue, Marie-Hélène
Macintyre, Elizabeth https://orcid.org/0000-0003-0520-0493
Callanan, Mary
Jerkeman, Mats
Unterhalt, Michael
Hoster, Eva https://orcid.org/0000-0002-0749-1389
Dreyling, Martin
Le Gouill, Steven
Hermine, Olivier
Cheminant, Morgane https://orcid.org/0000-0002-2070-9581
- License Information
-
More Information
Article History
Received: 4 October 2024
Revised: 23 January 2025
Accepted: 20 February 2025
First Online: 24 April 2025
Competing interests
: MC reports honoraria from Amgen, CSL Behring, Astra Zeneca, Lilly, and Abbvie; research funding from Innate Pharma, Force Hemato, and Servier; travel and accommodation expenses from Pfizer, Griffols, CSL Behring, Astra Zeneca, Lilly, and Gilead but no competing financial interests for this study. FM reports consultancy for Roche/Genentech; and advisory boards for Roche, BMS, Gilead, Novartis, Epizyme, Genmab, AbbVie, and Kymera. VS reports consultancy for Kite/Gilead, Janssen; fundings from Janssen, Abbvie. The remaining authors declare no competing financial interests for this study.
: Written informed consent was obtained from all participants, who were included in the previously published clinical trial (EU-MCL younger [] NCT00209222, LyMA [] NCT00921414, LyMA101 [] NCT02896582, EU-MCL elderly [] NCT00209209, RiBVD [] NCT01457144 and MCL-R2 [] NCT01865110). The studies were approved by an independent ethics committee and conducted in accordance with the Declaration of Helsinki.
